Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease

References

• Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342 (8873), 697–699 (1993).
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D et al Apolipoprotein E: high-avidity binding to 3-amyloid and increased frequency of Type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl Acad. Sci. USA 90(5), 1977-1981 (1993).
   Google Scholar
• Saunders AM, Strittmatter WJ, Schmechel D et al Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43(8), 1467–1472 (1993).
   Google Scholar
• Roher AE, Weiss N, Kokjohn TA et al Increased AP peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41 (37), 11080–11090 (2002).
   PubMed Web of Science ®Google Scholar
• Mason RP Shoemaker WJ, Shajenko L, Chambers TE, Herbette LG. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging13(3), 413–419 (1992).
   PubMedGoogle Scholar
• Distl. R, Meske V, Ohm TG. Tangle- bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol 101(6), 547–554 (2001).
   PubMedGoogle Scholar
• Gaudreault SB, Dea D, Poirier J. Increased caveolin-1 expression in Alzheimer's disease brain. Neurobiol Aging25(6), 753–759 (2004).
   Google Scholar
• ••Reported that an increase in caveolin-1 inthe Alzheimer's disease (AD) brain is an additional link between cholesterol homeostasis and amyloid precursor protein processing that is thought to occur in lipid rafts or caveolae.
   Google Scholar
• Kurzchalia TV, Dupree P, Parton RG et al VIP21, a 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. j Cell Biol. 118(5), 1003–1014 (1992).
   Google Scholar
• Bjorkhem I, Lutjohann D, Breuer 0, Sakinis A, Wennmalm A. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 1802 techniques in vivo and in vitiv. BiolChem. 272 (48), 30178–30184 (1997).
   Google Scholar
• Ando S, Tanaka Y, Toyoda Y, Kon K Turnover of myelin lipids in aging brain. Neurochem. Res. 28(1), 5–13 (2003).
   PubMedGoogle Scholar
• Kehoe P, Wavrant-De Vrieze F, Crook R et al A full genome scan for late onset Alzheimer's disease. Hum. Mal Genet. 8(2), 237–245 (1999).
   PubMedGoogle Scholar
• Poirier J. Cholesterol transport and synthesis are compromised in the brain in sporadic Alzheimer's disease: from risk factors to therapeutic targets. In: Alzheimer s disease and Related Disarlers Annual. Gauthier S, Cummings JL (Eds). Dunitz, NY, USA, 1–23 (2002).
   Google Scholar
• Poirier J, Hess M, May PC, Finch CE. Cloning of hippocampal poly(A) RNA sequences that increase after entorhinal cortex lesion in adult rat. Brain Res. Mal Brain Res. 9(3), 191–195 (1991).
   Google Scholar
• Blain JF, Paradis E, Gaudreault SB, Champagne D, Richard D, Poirier J. A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain. Neumbiol Dis. 15(3), 510–519 (2004).
   Google Scholar
• •Proposes a new role for lipoprotein lipase in the injured brain, a role that fits in the apolipoprotein E (apoE)/low-density lipoprotein (LDL) receptor pathway of cholesterol homeostasis and recycling following an injury.
   Google Scholar
• Cheng HW, Jiang T, Brown SA, Pasinetti GM, Finch CE, McNeill TH. Response of striatal astrocytes to neuronal deafferentation: an immunocytochemical and ultrastructural study. Neuroscience 62(2), 425–439 (1994).
   PubMedGoogle Scholar
• Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mal Med. 9(3), 94–101 (2003).
   Google Scholar
• Poirier J, Baccichet A, Dea D, Gauthier S. Cholesterol synthesis and lipoprotein re-uptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55(1), 81–90 (1993).
   PubMedGoogle Scholar
• •One of the first reports showing that a lesion in the brain was affecting cholesterol homeostasis as measured by changes in apoE levels, LDL receptor binding, hydroxy-methylglutaryl coenzyme A reductase activity and cholesterol esterification.
   Google Scholar
• Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Nut& 136,107–122 (1995).
   Google Scholar
• Chang TY, Chang CCY, Cheng D. Acyl- Coenzyme A: cholesterol acyltransferase. Ann. Rev. Biochem. 66,613-638 (1997).
   Google Scholar
• Uelmen PJ, Oka K, Sullivan M, Chang CC, Chang TY, Chan L. Tissue-specific expression and cholesterol regulation of acylcoenzyme A: cholesterol acyltransferase (ACAT) in mice. Molecular cloning of mouse ACAT cDNA, chromosomal localization, and regulation of ACAT in vivo and in vitro. Biol. Chem. 270(44), 26192–26201 (1995).
   Google Scholar
• Lutjohann D, Breuer 0, Ahlborg G et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Floc. Natl Acad. Li. USA 93(18), 9799–9804 (1996).
   Google Scholar
• Schonknecht P, Lutjohann D, Pantel J et al Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci. Lett. 324(1), 83–85 (2002).
   Google Scholar
• Bogdanovic N, Bretillon L, Lund EG et al On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neumsci. Lett. 314(1–2), 45–48 (2001).
   Google Scholar
• Desai P, DeKosky ST, Kamboh MI. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci. Lett. 328(1), 9–12 (2002).
   Google Scholar
• Papassotiropoulos A, Streffer JR, Tsolaki M et al Increased brain 3-amyloid load, phosphorylated tau, and risk of Alzheimer's disease associated with an intronic CYP46 polymorphism. Anil. Neuml. 60(1), 29–35 (2003).
   Google Scholar
• Kolsch H, Lutjohann D, Ludwig M et al Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Ma/ Psychiatry7(8), 899–902 (2002).
   Google Scholar
• Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like 3-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neural 126(1), 88–94 (1994).
   Google Scholar
• ••One of the first studies to directly linkcholesterol homeostasis and amyloid biology. Shows that modulating peripheral cholesterol levels can have a dramatic effect on central amyloid production and deposition.
   Google Scholar
• Schmechel D, Sullivan P, Mace B, Sawyer J, Rudel L. High saturated fat diets are associated with Ap deposition in primates. Presented at the 9th International Conference on Alzheimer's disease and Related Disorders. Stockholm, Sweden (2002).
   Google Scholar
• Refolo LM, Pappolla MA, Malester B et al Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neumbial Dis. 7(4), 321–331 (2000).
   Google Scholar
• Shie FS, Jin LW Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain A3 accumulation in transgenic mice. Neuromport 13(4), 455–459 (2002).
   Google Scholar
• Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of 3-amyloid in hippocampal neurons. Proc. Natl Acad. SclUSA 95(11), 6460–6464 (1998).
   Google Scholar
• Nishiyama K, Trapp BD, Ikezu T et al Caveolin-3 upregulation activates p-secretase-mediated cleavage of the amyloid precursor protein in Alzheimer's disease. Neurosci. 19(15), 6538–6548 (1999).
   Google Scholar
• Kojro E, Gimpl G, Lammich S, Marz W Fahrenholz E Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the a-secretase ADAM 10. Floc. Natl Acad. Sci. USA 98(10), 5815–5820 (2001).
   Google Scholar
• Marlow L, Cain M, Pappolla MA, Sambamurti K. 3-secretase processing of the Alzheimer's amyloid protein precursor (APP). Mal Neurosci 20(3), 233–239 (2003).
   Google Scholar
• Wahrle S, Das P, Nyborg AC et al Cholesterol-dependent y-secretase activity in buoyant cholesterol-rich membrane microdomains. Neumbial Dis. 9(1), 11–23 (2002).
   Google Scholar
• Puglielli L, Konopka G, Pack-Chung E et al Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid 3-peptide. Nature Cell Biol. 3(10), 905–912 (2001).
   Google Scholar
• Gibson WW, Eckert GP, Igbavboa U, Muller WE. Amyloid 3-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim. Biophys. Acta 1610(2), 281–290 (2003).
   Google Scholar
• •Reviews how cholesterol homeostasis and amyloid biology interplay on each other.
   Google Scholar
• Igbavboa U, Pidcock JM, Johnson LN et al Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and aged amyloid 3-peptide-(1–42). j Biol. Chem. 278(19), 17150–17157 (2003).
   Google Scholar
• Liu Y, Peterson DA, Schubert D. Amyloid p peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl Acad. Sci. USA 95,13266–13271 (1998).
   Google Scholar
• Howland DS, Trusko SP, Savage MJ et al Modulation of secreted 3-amyloid precursor protein and amyloid 3-peptide in brain by cholesterol. j Biol. Chem. 273(26), 16576–16582 (1998).
   Google Scholar
• Beffert U, Aumont N, Dea D, Lussier- Cacan S, Davignon J, Poirier J. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res. Mal Brain Res. 68(1–2), 181–185 (1999).
   Google Scholar
• Holtzman DM, Bales KR, Tenkova T et al Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci USA 97(6), 2892–2897 (2000).
   Google Scholar
• Fryer JD, Taylor JW, DeMattos RB et al Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. Neumsci. 23(21), 7889–7896 (2003).
   Google Scholar
• DeMattos RB, Cirrito JR, Parsadanian M et al ApoE and clusterin cooperatively suppress A3 levels and deposition. evidence that apoE regulates extracellular A3 metabolism in vivo. Neuron 41 (2), 193–202 (2004).
   Google Scholar
• ••Elegantly describes the role played byapoE and Jon amyloid deposition and clearance. This is the first in vivo evidence that apoE is directly involved in B-amyloid removal.
   Google Scholar
• Champagne D, Pearson D, Dea D, Rochford J, Poirier J. The cholesterol-lowering drug Probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience 121(1), 99–110 (2003).
   PubMedGoogle Scholar
• Mak PA, Laffitte BA, Desrumaux C et al Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors a and 3. Riol. Chem. 277(35), 31900–31908 (2002).
   Google Scholar
• Laffitte BA, Repa JJ, Joseph SB et al LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci USA 98 (2), 507–512 (2001).
   Google Scholar
• Sun Y, Yao J, Kim TW, Tall AR. Expression of liver X receptor target genes decreases cellular amyloid p peptide secretion. Chem. 278(30), 27688–27694 (2003).
   Google Scholar
• Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM. Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. j Neurosci. Res. 68(3), 331–336 (2002).
   Google Scholar
• Fassbender K, Simons M, Bergmann C et al Simvastatin strongly reduces levels of Alzheimer's disease fi-amyloid peptides AP 42 and AP 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98(10), 5856–5861 (2001).
   Google Scholar
• Refolo LM, Pappolla MA, LaFrancois J et al A cholesterol-lowering drug reduces P-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobial Dis. 8(5), 890–899 (2001).
   Google Scholar
• Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. NY Acad. Sri 802,101–110 (1996).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JA1VIA 291(3), 317–324 (2004).
   Google Scholar
• Rockwood K, Kirkland S, Hogan DB et al Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neural 59(2), 223–227 (2002).
   PubMed Web of Science ®Google Scholar
• Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neural 57(10), 1439–1443 (2000). First study to report an association between the use of statins and the decreased prevalence of AD. Since it was published, clinical trials specifically designed at evaluating statins effect in AD were initiated.
   Google Scholar
• Fassbender K, Stroick M, Bertsch T et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59(8), 1257–1258 (2002).
   PubMedGoogle Scholar
• Sparks DL, Connor D, Lopez J et al Benefit of atorvastatin in the treatment of Alzheimer's disease. Presented at the 8th International Montreal/Springfield Symposium on Advances in Alzheimer Therapy. Montreal, Canada (2004).
   Google Scholar
• Poirier J, Panisset M. Apolipoprotein E: a novel therapeutic target for the treatment of Alzheimer's disease. In: Mapping- the Progness of Alzheimels and Paddnson's Disease. Mizuno Y, Fisher A, Hanin I (Eds). Kluwer Academic/Plenum Publishers, NY, USA, 39–43 (2002).
   Google Scholar
• Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 (4978), 279–282 (1990).
   PubMed Web of Science ®Google Scholar
• Poirier J, Hess M, May PC, Pasinetti GM, Finch CE. Astroglial gene expression during reactive synaptogenesis. In: Basic and Therapeutic Strategies in Alzheimer's and Parkinson's Diseases. NY, USA, 191–194 (1990).
   Google Scholar